Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUCENT 3 long-term extension of mirikizumab in ulcerative colitis
NL-OMON54755Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mirikizumab in autoimmune colitis, sponsored by Eli Lilly and Company. Primary endpoint: Proportion of patients in clinical remission at Week 52. Started Oct 2018; status: recruiting.
02
Drugs
mirikizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON54755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54755.